In the present study, we have shown that treatment of a spontaneous murine EOC model (MISIIR) with a class I HDAC inhibitor upregulates tumor cell antigen expression and improves CD8 T cell function, while also reducing expression of suppressive myeloid chemoattractants. Here, CD8A is linked to neoplasm.